西班牙指南:靶向深度测序在MDS和CMML中的应用
西班牙MDS工作组(GESMD)发布指南,旨在为二代测序(NGS)在骨髓增生异常综合征(MDS)和慢性粒单核细胞白血病(CMML)中的临床应用建立质量标准。指南强调MDS和CMML中复发性基因突变见于>80%的患者,有助于分类和风险分层,并规范NGS数据的生成、分析、临床解读和报告。
要点
- MDS和CMML中复发性基因突变见于>80%的患者,有助于分类和风险分层。
- 指南旨在标准化NGS数据生成、分析、临床解读和报告的质量标准。
- 临床实验室已将NGS基因组分析纳入常规实践以个性化诊疗。
核心结论
- GESMD扩展指南以建立NGS在MDS和CMML中应用和结果临床解读的共通质量标准。
研究设计与样本
- 西班牙MDS工作组(GESMD)制定的指南,基于NGS技术进展和临床实践需求。
主要发现
- MDS和CMML中复发性基因突变见于>80%的患者,有助于更好的分类和风险分层。
关键数值与推荐
- 指南推荐标准化NGS数据的生成、分析、临床解读和报告。
临床怎么用
- 临床实验室应将NGS基因组分析纳入常规实践,以个性化MDS和CMML的诊断、预后和治疗。
局限性
- NGS技术的临床验证面临挑战,因技术不断进步。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The landscape of medical sequencing has rapidly changed with the evolution of next generation sequencing (NGS). These technologies have contributed to the molecular characterization of the myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), through the identification of recurrent gene mutations, which are present in >80% of patients. These mutations contribute to a better classification and risk stratification of the patients. Currently, clinical laboratories include NGS genomic analyses in their routine clinical practice, in an effort to personalize the diagnosis, prognosis and treatment of MDS and CMML. NGS technologies have reduced the cost of large-scale sequencing, but there are additional challenges involving the clinical validation of these technologies, as continuous advances are constantly being made. In this context, it is of major importance to standardize the generation, analysis, clinical interpretation and reporting of NGS data. To that end, the Spanish MDS Group (GESMD) has expanded the present set of guidelines, aiming to establish common quality standards for the adequate implementation of NGS and clinical interpretation of the results, hoping that this effort will ultimately contribute to the benefit of patients with myeloid malignancies.
引用
- Palomo L, Ibáñez M, Abáigar M, et al. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2019. PMID: 31621063. doi:10.1111/bjh.16175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。